Dexamethasone acetate
Based on 6 publication(s) in Google Scholar
Dexamethasone acetate (Dexamethasone 21-acetate) is the acetate form of the glucocorticoid Dexamethasone (HY-14648). Dexamethasone acetate has a longer duration of action than Dexamethasone. Dexamethasone acetate can accumulate at inflammatory sites, in mouse liver and mouse lung via nanostructured lipid carriers. Dexamethasone acetate can be used to prepare topical formulations for studies related to sensorineural hearing loss, γ-carrageenan-induced paw edema, chronic active hepatitis, pulmonary diseases, and inflammation after vitreoretinal surgery.
For research use only. We do not sell to patients.
- Purity: 99.86%
- CAS No.: 1177-87-3
- Formula: C24H31FO6
- Molecular Weight:434.50
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
FDA-Approved Drug Library
HY-L022
-
CNS-Penetrant Compound Library
HY-L028
-
Drug Repurposing Compound Library
HY-L035
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Exosomes Compound Library
HY-L072
-
Nuclear Receptor Compound Library
HY-L126
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Osteogenesis Compound Library
HY-L131
-
Pain-Related Compound Library
HY-L139
-
Off-patent Drug Library
HY-L141
-
Mitochondrial Protection Compound Library
HY-L144
-
Extracellular Vesicles (EVs) Compound Library
HY-L168
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Steroid Hormones Library
HY-L239
Publications Citing Use of MedChemExpress (MCE) Dexamethasone acetate
More
Customer Validation & Images
-
ELISA
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
-
Bio/Physico-chemical Assay
-
IHC
Biological Activity
Glucocorticoid receptor[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | EC50 |
4.5 μM
Compound: Dexamethasone acetate
|
Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis
Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis
|
[PMID: 20966043] |
Dexamethasone acetate (28.2 mg particles in 150 mL water; 37 days; 5 separate samples in 45 mL water; 26 days) encapsulated in PLGA-magnetite nanoparticles releases a total of 37.8% of particle weight as Dexamethasone equivalent over 37 days in aqueous solution, with 2% to 23% of particle weight released over 26 days in replicate experiments[1].
Dexamethasone acetate (2 h; 48 h) loaded solid lipid nanoparticles exhibit an initial burst release of ~68% over 2 h followed by gradual release over 48 h in pH 7.4 phosphate buffer saline at 37°C[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
DA-NLCs (3 mg/kg; i.v.; single dose) deliver Dexamethasone acetate (DA) to inflamed pleural sites at concentrations 8.3 times higher than free DA, with a 10.6-fold larger AUC0-t and prolonged residence time at the inflammatory site[2].
DA-NLCs (7 mg/kg; i.v.; single dose) preferentially accumulate in mouse liver and lung tissues, achieving 1.8- to 2.6-fold larger AUC0-ts than free DA, and prolong DA residence time in plasma[2].
Dexamethasone acetate-loaded poly(ɛ-caprolactone) nanofibers (200 µg; intravitreous implantation via transscleral injection; single administration) exhibit excellent ocular biocompatibility and safety in the Rattus norvegicus eye, preserving retinal and choroidal structure and photoreceptor function over 10 days following intravitreous implantation[3].
Dexamethasone acetate (10 mg/kg; i.v.; single dose) delivered via solid lipid nanoparticles exhibits remarkable lung-targeting in healthy Kunming mice, with a 17.8-fold higher lung AUC0-t and 7.10 relative overall targeting efficiency compared to the free drug solution, while reducing uptake by liver and spleen macrophages[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1177-87-3
-
Appearance Solid
-
Molecular Weight 434.50
-
Formula C24H31FO6
-
Color White to off-white
-
SMILES
C[C@@]1([C@@]2(O)C(COC(C)=O)=O)[C@](C[C@H]2C)([H])[C@@](CCC3=CC4=O)([H])[C@@](F)([C@]3(C=C4)C)[C@@H](O)C1
-
Synonyms
Dexamethasone 21-acetate; Hexadecadrol acetate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
ACS Appl Mater Interfaces
Spatiotemporal Circadian Oscillator Manipulation for Enhanced Ovarian Cancer Therapy Using a Versatile Nanoplatform. [Abstract]2025 Jun 18;17(24):35023-35039. PMID: 40488667 -
Free Radic Biol Med
Salvianolic acid B drives gluconeogenesis and peroxisomal redox remodeling in cardiac ischemia/reperfusion injury: A metabolism regulation by metabolite signal crosstalk. [Abstract]2025 Mar 1:229:399-414. PMID: 39855316 -
Phytother Res
Sappanone A Exerted Strong Anti-Inflammatory Effects in the Treatment of Atopic Dermatitis Through IL-21R-Mediated JAK1/STAT3 Pathway. [Abstract]2025 Nov 14. PMID: 41236101
Dexamethasone acetate purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Nov 14. [Abstract]
The protein levels of IL-1β, IL-25, IL-33, and TSLP were detected by ELISA assays. HaCaT cells were treated with various concentrations of SA, Dexamethasone acetate (DEX, 50 μM), or left untreated under IL-4/IL-13/TNF-α stimulation.
Dexamethasone acetate purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Nov 14. [Abstract]
The body weight in each group were measured at specific time points. The results showed that Dexamethasone acetate (DEX, 2.5 mg/kg; topical application) treatment further exacerbated the weight loss caused by MC903.
-
J Ethnopharmacol
The anti-inflammatory potential of Cinnamomum camphora (L.) J.Presl essential oil in vitro and in vivo. [Abstract]2021 Mar 1;267:113516. PMID: 33141054 -
-
Dexamethasone acetate purchased from MedChemExpress. Usage Cited in: MedComm Futur Med. 2024 Jul 19.
Representative images of lung tissue stained with hematoxylin and eosin. The results showed that dexamethasone acetate (Dexm, 5 mg/kg; i.g.; once daily for 3 weeks) effectively alleviated the severe alveolar hemorrhage, edema, thickening of alveolar septa, and inflammatory cell infiltration induced by bleomycin instillation.
Dexamethasone acetate purchased from MedChemExpress. Usage Cited in: MedComm Futur Med. 2024 Jul 19.
Dexamethasone acetate (Dexm, 5 mg/kg; i.g.; once daily for 3 weeks) effectively inhibited the bleomycin-induced elevation of serum levels of inflammatory cytokines—such as IL-1β, IL-6, and TNF-α—in mice with pulmonary fibrosis.
Dexamethasone acetate purchased from MedChemExpress. Usage Cited in: MedComm Futur Med. 2024 Jul 19.
Representative immunohistochemical images of transforming growth factor β (TGF-β), α-smooth muscle actin (α-SMA), and collagen type I alpha 1 (Col1a1) in lung tissues. The results showed that Dexamethasone acetate (Dexm, 5 mg/kg; i.g.; once daily for 3 weeks) significantly inhibited the bleomycin-induced upregulation of TGF-β, α-SMA, and Col1a1 expression in mouse lung tissue.
Solvent & Solubility
DMSO : 50 mg/mL (115.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.79 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.79 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Mice[3]
Female C57Bl/6JBom mice (age 10-12 weeks) are used in all experiments. Dexamethasone is administered as a single injection of 1 or 10 mg/kg. Dexamethasone is dissolved in saline and 400 μL are injected intraperitoneally, either 1 h before or 1 h after LPS exposure. In one experiment, N-acetylcysteine (NAC) (100 and 500 mg/kg) is injected successively every 4•5 h, starting 1 h before challenge (five injections in total). A control group of LPS-exposed animals are injected intraperitoneally with solvent alone (saline). Intratracheal administration is performed by instillation of 100 μL NAC (50, 100 or 500 mg/kg) or Dexamethasone (10 mg/kg) into the lungs of mice anaesthetized with 15 mg/kg Rapinovet (i.v.).
Rats[4]
Male Sprague-Dawley rats are used.Dexamethasone-treated rats are injected intraperitoneally once daily with Dexamethasone (1.5 mg/kg body weight) for 5 days and are allowed to feed ad libitum. The Dexamethasone dose (1.5 mg/kg/day) and the duration of treatment (5 days) are specifically chosen as this treatment induced a reproducible and marked catabolic state. Control rats received no treatment and are fed ad libitum. In order to take into account the decrease in food intake induced by Dexamethasone treatment, a third group of pair-fed rats are used. These rats are provided with the same amount of food as Dexamethasone-injected rats and are treated with a daily isovolumic intraperitoneal injection of NaCl (0.9%) for 5 days. After the final injection of Dexamethasone or NaCl, the animals are fasted overnight prior to being killed by decapitation.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (284 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Portuguese - PT (419 KB)
-
Handling Instructions (2659 KB)
References
[1]. Du X, et al. Magnetic targeted delivery of dexamethasone acetate across the round window membrane in guinea pigs. Otol Neurotol. 2013;34(1):41-47. [Content Brief]
[2]. Xu X, et al. Anti-inflammatory activity of injectable dexamethasone acetate-loaded nanostructured lipid carriers. Drug Deliv. 2011;18(7):485-492. [Content Brief]
[3]. Da Silva GR, et al. Ocular biocompatibility of dexamethasone acetate loaded poly(ɛ-caprolactone) nanofibers. Eur J Pharm Biopharm. 2019;142:20-30. [Content Brief]
[4]. Xiang QY, et al. Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles. Arch Pharm Res. 2007;30(4):519-525. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3015 mL | 11.5075 mL | 23.0150 mL | 57.5374 mL |
| 5 mM | 0.4603 mL | 2.3015 mL | 4.6030 mL | 11.5075 mL | |
| 10 mM | 0.2301 mL | 1.1507 mL | 2.3015 mL | 5.7537 mL | |
| 15 mM | 0.1534 mL | 0.7672 mL | 1.5343 mL | 3.8358 mL | |
| 20 mM | 0.1151 mL | 0.5754 mL | 1.1507 mL | 2.8769 mL | |
| 25 mM | 0.0921 mL | 0.4603 mL | 0.9206 mL | 2.3015 mL | |
| 30 mM | 0.0767 mL | 0.3836 mL | 0.7672 mL | 1.9179 mL | |
| 40 mM | 0.0575 mL | 0.2877 mL | 0.5754 mL | 1.4384 mL | |
| 50 mM | 0.0460 mL | 0.2301 mL | 0.4603 mL | 1.1507 mL | |
| 60 mM | 0.0384 mL | 0.1918 mL | 0.3836 mL | 0.9590 mL | |
| 80 mM | 0.0288 mL | 0.1438 mL | 0.2877 mL | 0.7192 mL | |
| 100 mM | 0.0230 mL | 0.1151 mL | 0.2301 mL | 0.5754 mL |
Dexamethasone acetate Related Classifications
Cat. No.: HY-14648A
Powered by Bioz
- Dexamethasone
- 1177-87-3
- Dexamethasone 21-acetate
- Hexadecadrol
- Glucocorticoid Receptor
- retinal cells
- human MIO-M1 cells
- human ARPE-19 cells
- γ-carrageenan-induced paw edema
- chronic active hepatitis
- sensorineural hearing loss
- mouse liver
- glucocorticoid steroid
- mouse lung
- guinea pig cochlear tissues
- Inhibitor
- inhibitor
- inhibit